Introduction
Scleroderma (systemic sclerosis, SSc) is a multifactorial autoimmune disorder, which is thought to be triggered in a genetically predisposed individual by an environmental event. The disease is characterized by microvascular injury and excessive extracellular matrix deposition in the skin and visceral organs, mainly gastrointestinal tract, lungs, heart and kidneys.
1 SSc is relatively rare (incidence: 1-2 per 100 000 person-years) but is associated with significant mortality, with a median survival time of approximately 11 years. Women are afflicted approximately three times as often as men, and even more often during the late childbearing years. 2, 3 Little is clearly understood about the pathogenesis of SSc, but existing evidence suggests that T cells may play important roles in the disease development. Histopathological findings of early lesions from SSc patients is characterized by fibroblast activation, endothelial cell alteration and tissue infiltration with activated immune cells, particularly with T cells populating around perivascular areas and adjacent to fibroblasts. 1, 4 Moreover, in systemic circulation of patients, elevated levels of activated T-cell products, for example, interleukin (IL)-2 and IL-2 receptor, have been observed. 5 T cells, by producing soluble mediators or cytotoxic effects, can participate in fibrosis and endothelial injury in SSC patients. 1 Furthermore, T cells may be involved in autoantibody formation in patients with SSc. In this regard, recently, an association between a T-cell coreceptor (CTLA-4) gene and presence of anti-U1-RNP autoantibody has been reported. 6 Consistent with these findings in humans, evidence from animal models suggests that T cells are responsible for the development of scleroderma-like lesions at least in two animal models. 7, 8 However, in humans, it is still a question that activation of immune cells is a cause or is secondary to initiating antigens or antigen expressed as a consequence of the disease process. 9 If genetic factors involved in Tcell signaling prove to contribute to the development of disease, then one can argue that immune activation in SSc may partly be owing to an intrinsic abnormality of T cells. To date, several genes have contributed to SSc development, notably genes of HLA, platelet-derived growth factor, IL-8, CXCR-2, fibrillin 1, angiotensinconverting enzyme, endothelial nitric oxide synthase, microsattellite markers near transforming growth factor (TGF-b) genes [10] [11] and recently CTLA-4.
6,12
CTLA-4 gene is located on chromosome 2q33 13 and is expressed transiently on activated T cells and constitutively on regulatory T (Tr) cells. CTLA-4 interacts with the B7 cell surface molecule on antigen-presenting cells and inhibits T-cell activation and proliferation.
14 It has been shown that germline disruption of the CTLA-4 gene induces systemic lymphoproliferative disorders and early death in mice. 15 The definite mechanism of CTLA-4-mediated T-cell inhibition is not fully understood. It is known, however, that CTLA-4 reduces the positive costimulatory signal delivered by CD28 through competition for ligand binding and interfering with downstream signaling molecules. Other mechanisms by which this molecule can negatively regulate T-cell functions include interfering with signals delivered by T-cell receptors (TCR), blocking IL-2 production, promotion of T-cell apoptosis, 14 inhibition of dendritic cell function by inducing tryptophan catabolism 16 and induction of immune suppressive cytokine TGF-b. 17 Moreover, CTLA-4 can regulate T-cell polarization to Thelper (Th) 1 or Th2 by controlling the overall strength of T-cell activation signal. In this regard, it has been shown that strong TCR signals and CD28 costimulation induce Th2 polarization, whereas ligation of immune attenuator CTLA-4 promotes Th1 polarization. The impact of CTLA-4 on T-cell polarization is further supported by a shifting towards Th2 polarization in germline CTLA-4-deficient mice. 18 Several studies have shown that specific CTLA-4 gene polymorphisms confer susceptibility to several autoimmune diseases, such as Graves' disease, 19 type 1 diabetes, 20 systemic lupus erythematosus 21, 22 and SSc. 6, 12 In a recent study, we were unable to show any association between CTLA-4 þ 49 polymorphism and SSc in Iranian population. 23 To further explore the role of the gene in SSc development, in the present study, we investigated whether the polymorphisms in the promoter region of CTLA-4 gene (À1722 T/C, À1661 A/G and À318 C/T) were associated with susceptibility to the disease in the Iranian population.
Results
All investigated genotype frequencies were not significantly deviated from the Hardy-Weinberg equilibrium (HWE) in both patients and control group. It is worth mentioning that testing for deviations from HWE is an important requirement in population genetic studies, particularly for the control group. Deviation from HWE in control subjects could result from many factors, notably genotyping errors, population stratification and racial/ethnic heterogeneity. 24 As indicated in Table 1 , a significant association of all three investigated polymorphisms was found with SSc disease. In the case of À1722 T/C polymorphism, frequencies of the TC genotype were significantly higher in patients in comparison to control group. (25.3 vs 13.9%, respectively; P ¼ 0.022). The C allele at this position was also significantly more frequent in patients with SSc compared to healthy controls (13.9 vs 6.9%, respectively; P ¼ 0.012, odds ratio (OR) ¼ 2.16, 95% confidence interval ¼ 1.17-3.98).
With respect to À1661 polymorphism, the frequencies of the AG genotype were significantly higher in patients than control subjects (25.3 vs 13.3%, respectively; P ¼ 0.03). The G allele at this position had also significant higher frequencies in SSc patients compared to the controls (16.3 vs 9.6%, respectively; P ¼ 0.031, OR ¼ 1.82, 95% confidence interval ¼ 1.05-3.15).
In the case of À318 C/T polymorphism, the significant increase of the TC genotype frequencies was found in patients compared to control group (16.9 vs 6.0%, respectively; P ¼ 0.014). The T-allele frequency was also significantly increased in SSc patients compared to the control subjects (8.4% vs 3.6, respectively;
After comparing genotype combinations of these three polymorphisms, a significant difference in the frequency of wild-type homozygous genotype combination (TT AA CC, for À1722, À1661 and À318 left to right, respectively) was observed between patients and control subjects. Frequency of this genotype combination appeared to be significantly increased in the control group in comparison to patients (69.9 vs 45.8%, P c ¼ 0.003) ( Table 2) .
Furthermore, as indicated in Table 3 , there was no significant difference between genotypic frequencies of Table 1 Comparison of genotype and allele frequencies in SSc patients and controls 
Discussion
Results of this investigation revealed significant differences in genotype and allele frequencies of CTLA-4 gene promoter (À1722 T/C, À1661 A/G and À318 C/T) between SSc patients and healthy individuals. Statistical analyses indicate increased heterozygous genotypes and mutant alleles in SSc patients, from one side, and increased wild-type homozygous genotypes and wildtype alleles in controls subjects, from the other side. In addition, the wild-type homozygous 'genotype combination' of these three loci occurred more frequently in the control group than in SSc patients (P c ¼ 0.003). The mutant homozygous genotypes were rare in both patients and control group.
Several transcription factors have been suggested to regulate CTLA-4 gene expression including NFAT, AP-1, 2, STAT, GATA-1, NF-kB and Oct-1. An IL-4-negative regulatory element has also been identified in the regulatory region of CTLA-4 gene. Moreover, CTLA-4 expression is increased by cAMP, suggesting a cAMPdependent regulation of CTLA-4 gene expression. 14 Significant increase of the CTLA-4 mutant alleles (À1722C, À1661G and À318T) and heterozygous genotypes (À1722 T/C, À1661 A/G and À318 C/T) in SSc patients rather than controls suggests that cytosine at position À1722, guanine at position À1661 and thymine at position À318 may affect the transcription level of the gene. In this regard, an association between CTLA-4 promoter genotypes at position À318 and levels of CTLA-4 molecule has been demonstrated. 25, 26 However, the two variants of this SNP were not predicted to be a binding site for homo sapiens transcription factors (http://mbs.cbrc.jp/research/db/TFSEARCH.html). Alternatively, the associations observed here might Association of CTLA-4 gene promoter polymorphisms S Almasi et al be related to linkage disequilibrium between the CTLA-4 alleles at these positions and those of a putative locus for SSc. Analysis of the data from patients' sib by transmission disequilibrium tests may assist in evaluating this possibility. CTLA-4 gene promoter polymorphisms have been associated with the risk of several autoimmune diseases. [19] [20] [21] [22] Fernandez-B et al. reported the association of À1722 T/C polymorphism of CTLA-4 gene promoter with SLE disease in Spanish population. Consistent with our findings in SSc, this group reported higher frequency of À1722 C allele in SLE patients compared to the controls (11.2 vs 4.9%, P ¼ 0.0004).
Hudson LL et al., 12 did not find any association between CTLA-4 gene (À1722 T/C, À1661 A/G and À318 C/T) polymorphisms and SSc in both CaucasianAmerican and African-American populations of South Carolina, while we found significant association. These conflicting results may be a reflection of genetic heterogeneity and potential differences in linkage disequilibrium among various racial populations. Although we were unable to show any association between SSc and the A to G polymorphism in CTLA-4 exon-1 in a previous study, 23 the observed association here, emphases on the importance of genetic markers in the promoter region and susceptibility to diseases.
CTLA-4 molecule has two important alternative splice transcripts: full-length transcript that encodes membrane-bound isoform (mCTLA-4), and a transcript lacking exon-3 (transmembrane region) that encodes soluble form of CTLA-4 (sCTLA-4). mCTLA-4 upon binding to B7 molecules inhibits CD28/B7 interaction, resulting in downregulation of the immune response, 14 whereas increase in sCTLA-4 levels may block B7-mCTLA-4 interactions and thereby enhances T-cell activation and autoreactivity. In this regard, Sato et al. 27 reported that increased levels of sCTLA-4 may be related to the abnormal immune response in SSc patients. It is possible that the mutant alleles of CTLA-4 gene promoter that associated with SSc susceptibility in our study can alter the balance between mCTLA-4 and sCTLA-4 through linkage disequilibrium with special sequences such as exon-3.
It has been reported that crosslinking of CTLA-4 on CD4 þ T cells results in marked increase in TGF-b production. 17 This multifunctional cytokine through its ability in stimulating extracellular matrix production can contribute to the extensive fibrosis in SSc. 28 Hudson et al. 12 suggested that CTLA-4 special genotypes in exon-1 could affect the crosslinkage efficacy of CTLA-4 molecules. CTLA-4 promoter mutant alleles, which are related to SSc, might enhance indirectly CTLA-4 crosslinkage efficacy leading to an increase in TGF-b secretion; however, a role of promoter region in this process remains to be investigated.
In conclusion, the mutant alleles of CTLA-4 gene promoter (À1722 T/C, À1661 A/G and À318 C/T) polymorphisms appear to be associated with SSc in Iranian population, and individuals carrying these alleles are more susceptible to this disease. To our knowledge, this is the first report that shows an association of these three CTLA-4 gene polymorphisms with SSc. To confirm this finding, serum and functional studies and a comprehensive case-control analysis from other ethnic groups are required.
Subjects and methods

Patients and controls
After informed consent, a total of 83 unrelated patients with SSc (76 females and seven males; mean age: 41712 years ranging 18-68 years) and 166 unrelated healthy subjects (152 females and 14 males; mean age: 41712 years ranging 18-68 years) participated in this study. All patients fulfilled the American Colleague of Rheumatology Criteria for SSc, 3 and who had overlap syndromes were excluded. Patients were recruited from the Rheumatology clinic at Hafez hospital, Shiraz. The mean age at onset of SSc was 33.7 years, ranging from 15 to 65 years. The disease duration was 8.277.4 years. As the onset of SSc is usually greater than 25 years, 1 patients were divided into two age groups, below and over 25. Ethnically matched subjects with no clinical evidence or family history of autoimmune diseases were recruited at Shiraz Blood Transfusion Service. All participating individuals in this study were belonged to the Parsses ethnic group of Iran.
DNA extraction
Peripheral blood samples were obtained from patients and controls. Genomic DNA was isolated from donated blood by proteinase K method.
Polymorphism typing of CTLA-4 promoter (À1722, À1661 and À318) Polymerase chain reaction (PCR) reactions were performed according to the previously described method. 29 PCR products were then resolved in a 2% agarose gel containing ethidium bromide (Figures 1-3 ).
Statistical analysis
The data were analyzed by Pearson's w 2 test and Fisher's exact test, using SPSS (version 11.5; SPSS Inc., Chicago, IL, USA). P-values of the genotype combinations were corrected (P c ) for the number of comparisons tested (Bonferroni method). The fit to the HWE were calculated using the Arlequin software. Statistical significance was defined as Po0.05. Association of CTLA-4 gene promoter polymorphisms S Almasi et al
